Find a Clinical Trial | Tufts Medicine

Filter

Showing 1 - 10 out of 30

DEFENDO Long-Term Follow-Up Study

A long-term extension study to evaluate the safety and efficacy of OXERVATE 0.002% (20 mcg/mL) cenegermin-bkbj ophthalmic solution in patients with Stage 1 Neurotrophic Keratitis who enrolled in the DEFENDO Study

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

Dompe' Reparixin study

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Moderna mRNA 1273 study

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

COVID-19

All genders

0-12

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

HGB-210

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

Sickle cell anemia

All genders

2-50

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Learn more

SEER-2

A Phase 3, Multi-Center, Randomized, Parallel, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of 0.1% RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy (SEER-2)

Neurotrophic keratitis

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

POETYK SjS-1

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults with Active Sjögren’s Syndrome (POETYK SjS-1)

Sjogren's syndrome

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

BALATON

A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion

Macular degeneration

All genders

18+

Recruiting now

Department of Ophthalmology

Learn more

Belvedere

A Phase IV, Multicenter, Open-label, Single-Arm study of the response to treatment after transition to the port delivery system with Ranibizumab (Susvimotom [Ranibizumab injection]) in patients with neovascular age-related macular degeneration previously treated with intravitreal agents other than Ranibizumab.

Macular degeneration

All genders

50+

Recruiting now

Department of Ophthalmology

Learn more

Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

Cytomegalovirus infection

All genders

18-75

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more